What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Breast cancer
Fatima Cardoso mostly deals with Breast cancer, Internal medicine, Oncology, Cancer and Surgery.
Her studies in Breast cancer integrate themes in fields like Gynecology and Clinical trial, Pathology.
Her work investigates the relationship between Internal medicine and topics such as Gene expression profiling that intersect with problems in Proportional hazards model and Clinical significance.
Her work deals with themes such as Metastatic breast cancer, Chemotherapy, Adjuvant therapy and Hazard ratio, which intersect with Oncology.
The Cancer study combines topics in areas such as Guideline and Radiation therapy.
In the field of Surgery, her study on Mucositis overlaps with subjects such as Temsirolimus and Ridaforolimus.
Her most cited work include:
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (1828 citations)
- Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis (1527 citations)
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (1526 citations)
What are the main themes of her work throughout her whole career to date?
The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer.
In her study, Gastroenterology is inextricably linked to Surgery, which falls within the broad field of Internal medicine.
Her study of MammaPrint is a part of Breast cancer.
In her study, Everolimus is strongly linked to Letrozole, which falls under the umbrella field of Oncology.
The study incorporates disciplines such as Hazard ratio and Intensive care medicine in addition to Cancer.
Her study in Metastatic breast cancer is interdisciplinary in nature, drawing from both Phases of clinical research, Metastasis and Family medicine.
She most often published in these fields:
- Internal medicine (63.09%)
- Breast cancer (63.30%)
- Oncology (56.91%)
What were the highlights of her more recent work (between 2018-2021)?
- Breast cancer (63.30%)
- Internal medicine (63.09%)
- Oncology (56.91%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Breast cancer, Internal medicine, Oncology, Cancer and Chemotherapy.
Fatima Cardoso studies MammaPrint, a branch of Breast cancer.
She combines topics linked to Gene signature with her work on Internal medicine.
Her work on Adjuvant is typically connected to Pembrolizumab as part of general Oncology study, connecting several disciplines of science.
Her Cancer research includes themes of Overall survival and Intensive care medicine.
Her study looks at the intersection of Chemotherapy and topics like Early breast cancer with Anthracycline.
Between 2018 and 2021, her most popular works were:
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (1526 citations)
- Pembrolizumab for Early Triple-Negative Breast Cancer. (228 citations)
- Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers (83 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Breast cancer
Her main research concerns Breast cancer, Internal medicine, Oncology, Cancer and Clinical trial.
The concepts of her Breast cancer study are interwoven with issues in Quality of life, Disease, Health care and Family medicine.
Her Disease study incorporates themes from Germline mutation and Epidemiology.
Her study in the field of Chemotherapy regimen also crosses realms of Pembrolizumab.
Her Cancer research integrates issues from Adverse effect and Radiation therapy.
Fatima Cardoso combines subjects such as Adjuvant and Neutropenia with her study of Metastatic breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
